Aimee Payne, MD
Dermatology · New York, NYNPI 1659396232
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $31,472 of the $37,636 with a category attached, or 83.6%. Janssen Research & Development, LLC accounts for 71.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $17,046 and has fallen 68.1% since, to $5,445 in 2025. Among dermatology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 24 payments — averaging $1568.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$27K
- E.r. Squibb & Sons, L.L.C.$5K
- Sanofi US Services Inc.$5K
- Kyowa Kirin, Inc.$150
- Regeneron Healthcare Solutions, Inc.$23
- Novartis$23
What the payments were for
- Consulting fees$31,47284%
- Speaking & faculty fees$5,12514%
- Travel & lodging$5101%
- Food & beverage$5291%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 17 | $26,890 |
| E.r. Squibb & Sons, L.L.C. | 1 | $5,425 |
| Sanofi US Services Inc. | 1 | $5,125 |
| Kyowa Kirin, Inc. | 3 | $150 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Novartis | 1 | $23 |
How this compares
$37,636 in reported general payments places this provider in the 90th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 17 | $69,833 |
| Clobetasol Propionate | 17 | $1,932 |
| Dexamethasone | 16 | $340 |
| Triamcinolone Acetonide | 19 | $284 |
| Ketoconazole | 15 | $281 |
| Prednisone | 14 | $75 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New York
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Joshua ZeichnerNew York$2.1M
- Emma GuttmanNew York$1.7M
- George HanNew York$1.6M
- Amy SpizuocoNew York$1.3M
- Andrew AlexisNew York$834K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.